{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["100(1)"],"submitter":["Gabrielle PH"],"funding":["la fondation de France"],"pubmed_abstract":["<h4>Purpose</h4>To report the 24-month outcomes of vascular endothelial growth factor (VEGF) inhibitors for myopic choroidal neovascularization (mCNV) in predominantly Caucasian eyes in routine clinical practice.<h4>Methods</h4>Retrospective analysis of treatment-naïve eyes starting intravitreal injection of VEGF inhibitors of either bevacizumab (1.25 mg) or ranibizumab (0.5 mg) for mCNV from 1 January 2006 to 31 May 2018 that were tracked in the Fight Retinal Blindness! registry.<h4>Results</h4>We identified 203 eyes (bevacizumab-85 and ranibizumab-118) of 189 patients. The estimated mean (95% CI) change in VA over 24 months for all eyes using longitudinal models was +8 (5, 11) letters with a median (Q1, Q3) of 3 (2, 5) injections given mostly during the first year. The estimated mean cha"],"journal":["Acta ophthalmologica"],"pagination":["e288-e296"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9290852"],"repository":["biostudies-literature"],"pubmed_title":["Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry."],"pmcid":["PMC9290852"],"pubmed_authors":["Nguyen V","Miguel L","Zarranz-Ventura J","Arnold J","Alforja S","Barthelmes D","Creuzot-Garcher C","Gabrielle PH","Casaroli-Marano RP","Sararols L","Gillies M"],"additional_accession":[]},"is_claimable":false,"name":"Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.","description":"<h4>Purpose</h4>To report the 24-month outcomes of vascular endothelial growth factor (VEGF) inhibitors for myopic choroidal neovascularization (mCNV) in predominantly Caucasian eyes in routine clinical practice.<h4>Methods</h4>Retrospective analysis of treatment-naïve eyes starting intravitreal injection of VEGF inhibitors of either bevacizumab (1.25 mg) or ranibizumab (0.5 mg) for mCNV from 1 January 2006 to 31 May 2018 that were tracked in the Fight Retinal Blindness! registry.<h4>Results</h4>We identified 203 eyes (bevacizumab-85 and ranibizumab-118) of 189 patients. The estimated mean (95% CI) change in VA over 24 months for all eyes using longitudinal models was +8 (5, 11) letters with a median (Q1, Q3) of 3 (2, 5) injections given mostly during the first year. The estimated mean cha","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-18T22:47:23.887Z","creation":"2022-08-05T07:03:16.121Z"},"accession":"S-EPMC9290852","cross_references":{"pubmed":["33960115"],"doi":["10.1111/aos.14893"]}}